Clinical trialNAWithdrawn
Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study
- Outcome
- Stopped earlyUnable to obtain Clinical Trial Certificate due to tech Unable to obtain Clinical Trial Certificate due to technical difficulties (Other)
- Phase
- NA
- Status
- Withdrawn
- Study type
- Interventional
- Start
- 2 February 2024
- Expected end
- 2 August 2026
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- pathologic response
- Sponsor
- Other
- Results posted
- No
- Last update
- 21 August 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 5
- BackgroundNeoadjuvant therapy for pancreatic cancer. DOI 10.1038/s41571-023-00746-1↗
- BackgroundImmediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
- BackgroundPathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations F… DOI 10.1097/pas.0000000000001853↗
- BackgroundPancreatic Cancer: A Review. DOI 10.1001/jama.2021.13027↗
- BackgroundMesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. DOI 10.1038/srep01870↗